Daily Respiratory Research Analysis
Analyzed 176 papers and selected 3 impactful papers.
Summary
A multicenter phase 2b RCT showed that oral nalbuphine significantly reduced objective cough frequency in idiopathic pulmonary fibrosis. Two high-impact translational studies advanced precision medicine: patient-matched lung tumouroids predicted therapeutic responses including CAR T activity, and a multi-trait, multi-ancestry genetic analysis improved discovery and polygenic risk prediction for asthma, COPD, and lung cancer.
Research Themes
- Symptom-targeted therapy in fibrotic lung disease
- Patient-derived organoid platforms for precision oncology
- Multi-ancestry genetics and polygenic risk prediction in respiratory disease
Selected Articles
1. Oral Nalbuphine in Idiopathic Pulmonary Fibrosis-Associated Cough: The CORAL Randomized Clinical Trial.
In a 52-site, double-blind phase 2b RCT (NCT05964335), nalbuphine ER at 27/54/108 mg twice daily for 6 weeks reduced objective 24-hour cough frequency in IPF-associated cough versus placebo, with relative decreases of 47.9%, 53.4%, and 60.2% versus 16.9%. The 54 mg and 108 mg doses also improved patient-reported cough frequency.
Impact: This is a high-quality multicenter RCT addressing a major unmet symptom in IPF, demonstrating objective and clinically relevant cough reduction with dose-response effects.
Clinical Implications: Nalbuphine ER may become a symptom-directed therapy for IPF-related chronic cough pending phase 3 confirmation, offering measurable reductions in cough burden with objective monitoring.
Key Findings
- Objective 24-hour cough frequency decreased by 47.9%, 53.4%, and 60.2% with 27, 54, and 108 mg nalbuphine ER vs 16.9% with placebo at 6 weeks.
- Patient-reported cough frequency improved at 54 mg (P=0.004) and 108 mg (P<0.005) vs placebo, with a non-significant trend at 27 mg.
- Trial randomized 165 patients across 10 countries; 160 were analyzed with digital cough monitoring for the primary endpoint.
Methodological Strengths
- Randomized, double-blind, placebo-controlled, multicenter phase 2b design
- Objective primary endpoint using digital cough monitoring with predefined analysis
Limitations
- Short 6-week treatment duration limits long-term efficacy and safety assessment
- Phase 2b study not designed for definitive clinical outcomes beyond cough measures
Future Directions: Conduct phase 3 trials to confirm efficacy, evaluate durability and safety, and assess broader quality-of-life and functional outcomes in IPF.
IMPORTANCE: For patients with idiopathic pulmonary fibrosis (IPF), cough impairs quality of life; effective treatments for IPF-associated cough are needed. OBJECTIVE: To determine if nalbuphine extended release (ER), a κ opioid receptor agonist and μ-opioid receptor antagonist, decreases cough compared with placebo in patients with IPF-associated cough. DESIGN, SETTING, AND PARTICIPANTS: In this randomized, double-blind, placebo-controlled phase 2b trial conducted at 52 sites in 10 countries, patients with IPF, chronic cough for at least 8 weeks, and a Cough Severity Numerical Rating Scale (0, no cough; 10, worst possible cough) score of 4 or higher were enrolled from February 2024 to February 2025, with last follow-up in April 2025. Statistical analyses were conducted from May to August 2025. INTERVENTION: Patients were randomized 1:1:1:1 to receive nalbuphine ER at doses of 27 mg, 54 mg, or 108 mg or placebo twice daily for 6 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was the relative change from baseline in 24-hour cough frequency (coughs/h), measured with a digital cough monitor, for nalbuphine ER compared with placebo at week 6. The key secondary outcome was the relative change from baseline in the patient-reported cough frequency (Evaluating Respiratory Symptoms in IPF cough subscale; scores range from 0-4, lower scores indicate lesser cough frequency) at week 6. RESULTS: Of the 223 patients screened, 165 were randomized (42, 43, 40, and 40 to receive nalbuphine ER 27 mg, 54 mg, and 108 mg, and placebo, respectively) and 160 were included in the primary analysis (median age, 71 [range, 51-85] years; 28.5% female). The baseline mean (SD) cough count was 28.3 (27.4) coughs/h. In the nalbuphine ER 27 mg, 54 mg, and 108 mg twice-daily groups, the mean relative decrease in the cough count and the absolute decrease in coughs/h were 47.9% (from 24.6 to 11.9; P = .008), 53.4% (from 28.0 to 14.9; P < .001), and 60.2% (from 31.5 to 11.9; P < .001), respectively, compared with placebo (16.9%; from 29.4 to 28.1 coughs/h). For the key secondary outcome of patient-reported cough frequency at week 6, the relative and absolute changes were -31.4% (from 2.3 to 1.5; P = .14), -40.6% (from 2.6 to 1.4; P = .004), and -40.2% (from 2.4 to 1.4; P < .005) in the 27-mg, 54-mg, and 108-mg groups, respectively, compared with -21.9% (from 2.6 to 1.9) with placebo. CONCLUSIONS AND RELEVANCE: For patients with IPF-associated chronic cough, all 3 doses of nalbuphine ER reduced objective cough frequency and the 2 higher doses improved patient-reported cough frequency at 6 weeks. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05964335.
2. Lung tumouroids as a testing platform for precision CAR T cell therapy.
Patient-matched lung tumouroids and healthy lung organoids preserved tumor identity and recapitulated individual responses to standard therapies. The platform revealed patient-specific CAR T cell responses driven by antigen density and tumor-intrinsic resistance programs, enabling rational selection and design of CAR T therapies for lung cancer.
Impact: Provides a validated, multi-omic patient-specific organoid platform that predicts therapeutic response and informs CAR T engineering, addressing key translational barriers in solid-tumor immunotherapy.
Clinical Implications: Supports preclinical testing to stratify patients for CAR T therapy and to optimize CAR design against resistance, potentially improving clinical trial success and personalizing lung cancer treatment.
Key Findings
- Lung tumouroids retained genomic, epigenomic, and proteomic identity of parental tumors and replicated standard-of-care therapy responses.
- Patient-specific CAR T responses were uncovered, influenced by target antigen density and tumor-intrinsic resistance programs.
- Matched healthy lung organoids and tumouroids provide a platform for rational patient selection and bespoke CAR T cell design.
Methodological Strengths
- Use of matched patient-derived tumouroids and healthy organoids with multi-omic validation
- Functional replication of patient-specific therapy responses including CAR T activity
Limitations
- Preclinical platform; lacks prospective clinical validation correlating model predictions with trial outcomes
- Potential limited generalizability depending on organoid derivation success and tumor sampling
Future Directions: Prospective studies integrating tumouroid-based selection into CAR T trials; expand antigen targets and resistance-mitigating CAR designs informed by the platform.
Lung cancer, the leading cause of cancer-related mortality, presents major challenges for both standard therapies and chimeric antigen receptor (CAR) T cell therapy due to tumour heterogeneity and resistance. Preclinical models that capture patient-specific factors are essential for personalizing treatment decisions. Here we show that matched lung tumouroids and healthy lung organoids derived from patients provide a robust platform for studying therapy responses. The tumouroids faithfully retained the molecular and histological identity of the original tumours, as confirmed by genomic, epigenomic and proteomic analyses, and accurately replicated individual patient responses to standard-of-care therapies. Importantly, the platform also revealed patient-specific CAR T cell responses, uncovering a complex interplay between target antigen density and broader, tumour-intrinsic resistance programmes. By capturing these individualized factors, our model supports rational patient selection for CAR T cell therapy in lung cancer and provides a framework for designing CAR T cells tailored to overcome resistance mechanisms in solid tumours.
3. Multi-trait and multi-ancestry genetic analysis of comorbid lung diseases and traits improves genetic discovery and polygenic risk prediction.
A multi-trait, multi-ancestry genetic analysis identified 25 new lung function loci in East Asians and introduced PRSxtra, which improved prediction of asthma, COPD, and lung cancer across ancestries in All of Us. The framework leverages pleiotropy to enhance discovery and polygenic risk prediction beyond trait- and ancestry-matched PRS approaches.
Impact: Demonstrates a scalable, equity-conscious genetic framework that improves respiratory disease risk prediction across diverse populations, addressing ancestry biases and enabling broader clinical translation.
Clinical Implications: Improved PRS performance across ancestries may enable more accurate stratification for prevention and screening in asthma, COPD, and lung cancer, contingent on clinical utility thresholds and implementation studies.
Key Findings
- Identified 25 new loci for lung function in East Asian ancestry using multi-trait, multi-ancestry analysis.
- Developed PRSxtra, a cross-trait and cross-ancestry PRS that improved prediction of asthma, COPD, and lung cancer in the All of Us multi-ancestry cohort.
- Demonstrated larger predictive gains in diverse populations compared with trait- and ancestry-matched PRSs.
Methodological Strengths
- Multi-trait and multi-ancestry approach leveraging pleiotropy to boost power
- External validation in a large, diverse All of Us cohort
Limitations
- Residual population stratification and phenotyping heterogeneity may influence estimates
- Clinical thresholds for actionability and implementation pathways remain to be established
Future Directions: Prospective evaluation of PRSxtra in clinical workflows, integration with environmental and clinical risk factors, and extension to underrepresented populations and additional respiratory phenotypes.
While respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma share many risk factors, most studies investigate them in isolation and in predominantly European-ancestry populations. Here, we conducted the most powerful multi-trait and multi-ancestry genetic analysis of respiratory diseases and auxiliary traits to date, identifying 25 new loci associated with lung function in individuals of East Asian ancestry. Using these results, we developed PRSxtra (cross-trait and cross-ancestry), a multi-trait and multi-ancestry polygenic risk score (PRS) approach that leverages shared components of heritable risk via pleiotropic effects. PRSxtra significantly improved the prediction of asthma, COPD and lung cancer compared to trait- and ancestry-matched PRSs in a multi-ancestry cohort from the All of Us Research Program, especially in diverse populations. Our results present a new framework for multi-trait and multi-ancestry studies of respiratory diseases to improve genetic discovery and polygenic prediction.